Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.37 |
| ▸ | RAB9A | P51151 | 13/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141590 | 1.00 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL13600516 | 0.99 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL4489342 | 0.84 | NPC1 (0.31) | NPC1 | |
| SCHEMBL4489335 | 0.84 | NPC1 (0.31) | NPC1 | |
| SCHEMBL13762558 | 0.74 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL3128705 | 0.72 | GNE (0.40) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL4489665 | 0.71 | HPGD (0.41) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL13523736 | 0.71 | RAB9A (0.39) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL3136957 | 0.69 | HPGD (0.40) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL13523629 | 0.69 | HPGD (0.42) | NPC1RAB9ASMN1; SMN2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022549-A1 | ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022549-A1 | ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE | H1-4, H1-5, H1-3 | NPC1 3934/4885RAB9A 4442/4885SMN1; SMN2 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.